Association for Accessible Medicines on Confirmation of Robert F. Kennedy Jr. as Secretary of Health and Human Services
A call to action to safeguard affordable generic and biosimilar medicines WASHINGTON (February 13, 2025) — The Association for Accessible Medicines today commented on the confirmation of Robert F. Kennedy Jr. as Secretary of the United States Department of Health and Human Services. The Senate voted today 52-48 to confirm Secretary Kennedy. “Making America healthy […]
Blog: Bill Addressing Drug Shortages Provides Long Overdue Relief from Penalties Hurting Generic Drug Market
Medicaid Inflation Penalties Exacerbate Challenges Faced by Generic Drug Manufacturers WASHINGTON (June 26, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today released a blog highlighting legislation currently being considered in the Senate Finance Committee that will correct an unintended consequence negatively impacting the generic drugs market […]
Senate Finance Committee Bill Addressing Drug Shortages Would Provide Long Overdue Relief from Penalties Hurting Generic Drug Market
While prescription drug shortages are multi-faceted, the issue continues to vex the American health care system, despite efforts from stakeholders to mitigate the problem. A range of experts from across the political divide have agreed that unsustainably low prices for generic drugs is contributing to the challenge. For instance, FDA Commissioner Califf recently said, “We […]
AAM Submits Comments to HHS and FTC on the Impact of GPOs and Wholesalers on Access to Generic Medicines
WASHINGTON (May 30, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today submitted comments to the U.S. Department of Health and Human Services and the Federal Trade Commission in response to a request for Information to better understand how the practices of pharmaceutical middlemen—group purchasing organizations and […]
AAM Commends HHS and FTC Call for Information and Solutions on Drug Shortages and Patient Access to Generics and Biosimilars
RFI asks what impact GPOs and drug wholesalers have on generic medication shortages WASHINGTON (February 14, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today commended the Federal Trade Commission and the U.S. Department of Health and Human Services in their efforts to understand generic drug shortages […]
AAM Statement on IQVIA Institute Report Examining Drug Shortages
WASHINGTON, D.C. (November 15, 2023) – The Association for Accessible Medicines (AAM) shared the following statement today in response to the IQVIA Institute’s release of a new analysis, Drug Shortages in the U.S. 2023: A Closer Look at Volume and Price Dynamics, which details the causes and impacts of shortages across a range of therapy […]
AAM White Paper on Shortages
Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the availability of generic medicines overall is remarkably stable – even during challenges such as the COVID-19 pandemic. Nonetheless, drug shortages, which hit crisis proportions between 2010 and 2011, can be a challenge for […]
U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability
Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the production of generic medicines overall has been remarkably stable – even during challenges such as the COVID-19 pandemic. Nonetheless, drug shortages, which hit crisis proportions between 2010 and 2011, can be a challenge […]
AAM All Access Podcast: Drug Shortages and the U.S. Supply Chain
AAM’s All Access Podcast lets us all learn from leaders and influential figures in health care. This series of candid, wide-ranging dialogues has given me a deeper appreciation of the dedication and brilliance of the men and women who take on the challenge of making prescription medicines more widely accessible. Only with access to prescription […]
How Inflation Penalties for Generic Medicines Could Worsen Drug Shortages
Amid rising health care costs, generic drugs stand out for delivering low-cost, affordable and accessible health care options for patients. As a result of robust head-to-head price competition that rapidly drives costs down to a fraction of the brand price, generics today comprise more than 90% of all prescriptions dispensed in the United States but […]
Generic and Biosimilar Industry Statement on Essential Medicines Executive Order
WASHINGTON, DC (August 6, 2020) — Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States. The generic industry already makes tens of billions of doses of safe, effective and affordable medicines here in America each year […]
Why—and How—the U.S. Should Develop a List of Essential Medicines
Compiling a list of medicines essential to the U.S. health care system is a key component of AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain After all, we can’t solve the problem unless we understand it. Currently there are approximately 20,000 prescription drugs. If policy makers wish to strengthen the supply […]
